MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights include:
“End market demand growth was strong for our Canadian pharmaceutical products in the first quarter of 2023 based on sales of our products by wholesalers to retailers during the priod, as reported by IQVIA,” commented Mr. René Goehrum, President and CEO of BioSyent. “This end market demand growth was not reflected in the 1% growth rate in our net revenues from sales to wholesalers during the first quarter, following strong growth in such sales to wholesalers in the fourth quarter of 2022. We are accustomed to such trade fluctuations in our Canadian pharmaceutical business from quarter to quarter as inventory moves through the supply chain. Our international pharmaceutical revenues continued to be lumpy with no exports during the first quarter of 2023 versus a comparatively strong Q1 2022, resulting in an 8% decline in total Company revenues overall. However, with continued demand growth in our Canadian pharmaceutical business, we are currently on track to deliver revenue growth in 2023. We also made significant investments during the quarter in current and coming new product launches. We are pleased to have launched FeraMAX® Pd Maintenance 45 in March 2023 with incremental revenue during the first quarter. We look forward to additional revenue generation from this and other new product launches in the near term, including a new women’s health product, as we execute on one of our key strategic objectives of portfolio diversification.”
The CEO’s presentation on the Q1 2023 Results is available at the following link: www.biosyent.com/q1-23/
The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2023 and 2022 will be posted on www.sedar.com on May 26, 2023.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
As of the date of this press release, the Company has 12,091,919 common shares outstanding.
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Comprehensive Income | ||||||
| In Canadian Dollars | Q1 2023 | Q1 2022 | % Change | |||
| Net Revenues | 6,482,694 | 7,037,411 | -8% | |||
| Cost of Goods Sold | 1,147,962 | 1,446,656 | -21% | |||
| Gross Profit | 5,334,732 | 5,590,755 | -5% | |||
| Operating Expenses and Finance Income/Costs | 3,735,758 | 3,440,580 | 9% | |||
| Net Income Before Tax | 1,598,974 | 2,150,175 | -26% | |||
| Tax (including Deferred Tax) | 423,728 | 562,271 | -25% | |||
| Net Income After Tax | 1,175,246 | 1,587,904 | -26% | |||
| Net Income After Tax % to Net Revenues | 18% | 23% | ||||
| EBITDA | 1,516,634 | 2,227,362 | -32% | |||
| EBITDA % to Net Revenues | 23% | 32% | ||||
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| AS AT | March 31, 2023 | December 31, 2022 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 26,249,485 | $ | 28,695,644 | -9 | % |
| Trade and other receivables | 3,878,584 | 3,498,355 | 11 | % | ||
| Inventory | 4,708,293 | 4,535,343 | 4 | % | ||
| Prepaid expenses and deposits | 413,672 | 254,958 | 62 | % | ||
| Loans receivable - current | 163,553 | 158,529 | 3 | % | ||
| Income tax recoverable | 179,632 | - | 100 | % | ||
| CURRENT ASSETS | 35,593,219 | 37,142,829 | -4 | % | ||
| Property and equipment | 1,601,781 | 1,673,036 | -4 | % | ||
| Intangible assets | 1,257,738 | 1,200,878 | 5 | % | ||
| Loans receivable - non current | 258,240 | 258,240 | 0 | % | ||
| Deferred tax asset | 37,763 | 210,281 | -82 | % | ||
| TOTAL NON CURRENT ASSETS | 3,155,522 | 3,342,435 | -6 | % | ||
| TOTAL ASSETS | $ | 38,748,741 | $ | 40,485,264 | -4 | % |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES | $ | 3,947,432 | $ | 5,719,314 | -31 | % |
| NON CURRENT LIABILITIES | 1,381,815 | 1,403,427 | -2 | % | ||
| Long term debt | - | - | 0 | % | ||
| Total Equity | 33,419,494 | 33,362,523 | 0 | % | ||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 38,748,741 | $ | 40,485,264 | -4 | % |
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
| Last Trade: | C$11.06 |
| Daily Change: | 0.05 0.45 |
| Daily Volume: | 1,501 |
| Market Cap: | C$128.190M |
September 20, 2024 August 26, 2024 May 16, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
